Abstract
The approach to the treatment of patients with metastatic renal cell carcinoma has changed dramatically during the past 5 years. In the past, efforts to treat metastatic renal cell carcinoma were directed at palliation using chemotherapy, hormonal agents, or radiation therapy to control symptoms. Metastatic renal cell cancer was often resistant to these agents. With the advent of biological response modifiers, an entirely different approach is now available. Both recombinant human interferon-alpha (IFA-alpha) and interleukin-2 (IL-2) have significant activity in advanced renal cell carcinoma. Treatment with IFN-alpha can be given as outpatient therapy and provides effective disease control in a substantial minority of cases. Treatment with IL-2-based therapy, although associated with significant acute toxicity, is capable of inducing durable remissions from this otherwise lethal disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
